Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
Tocainide hydrochloride (TONOCARD) is an oral Class IB antiarrhythmic agent structurally related to lidocaine, used to treat ventricular arrhythmias. It works by blocking sodium channels and reducing the automaticity of ectopic cardiac pacemakers. The drug is indicated for suppression of life-threatening ventricular arrhythmias in patients who have not responded to other antiarrhythmic agents.
With LOE approaching and modest competitive pressure (30%), the TONOCARD brand team is likely focused on lifecycle extension and defensive positioning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TONOCARD offers experience in mature product management, defensive competitive strategy, and lifecycle optimization in a declining market. Roles on this team typically focus on margin preservation, generic competition mitigation, and maintaining market share among specialized prescribers.
Worked on TONOCARD at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.